NCT05769946View on ClinicalTrials.gov

A Study of Hemay005 in Adult With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

January 24, 2024

Study Completion Date

February 21, 2024

Conditions
Hemay005, Atopic Dermatitis
Interventions
DRUG

Hemay005

A PDE-4 inhibitor

Trial Locations (1)

050000

First Hospital of Hebei Medical University, Shijiazhuang

Sponsors
All Listed Sponsors
lead

Ganzhou Hemay Pharmaceutical Co., Ltd

INDUSTRY